European Commission Approves Fixed-Duration Regimen of Calquence and Venetoclax for Chronic Lymphocytic Leukemia

The European Commission has approved a fixed-duration treatment regimen combining AstraZeneca’s Calquence (acalabrutinib) with venetoclax for patients diagnosed with chronic lymphocytic leukemia (CLL). This decision marks a significant regulatory milestone for the combination therapy, which is intended to provide an alternative treatment option for individuals living with this form of blood cancer.

The approval follows a thorough evaluation of clinical data supporting the efficacy and safety of the acalabrutinib-venetoclax combination. The fixed-duration approach aims to offer patients a defined treatment period rather than indefinite therapy, potentially reducing long-term side effects and improving overall quality of life. Chronic lymphocytic leukemia is one of the most common types of leukemia in adults, and advancements in targeted therapies like these are considered important developments in addressing unmet medical needs within this patient population.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: June 9, 2025

Related posts:

DrugPatentWatch.com Article: Early Engagement and Data-Driven Decisions Key to Expediting Biosimilar Approvals Kymera Therapeutics Reports Phase 1 Results Showing STAT6 Protein Reduction in Autoimmune Drug Trial Lectin-Based Screening Method Developed to Optimize Sialic Acid Glycosylation in Biopharmaceutical Production Pharma Companies Utilize Data and Omnichannel Strategies to Enhance Communication with Healthcare Professionals

Author

Mark Chiang